Sveriges mest populära poddar
Pharmaceutical Executive
VetenskapLife Science

Pharmaceutical Executive Daily: FDA's new Fast-Track Review

3 min•3 oktober 2025
In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.

Fler avsnitt av Pharmaceutical Executive

Visa alla avsnitt av Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Datroway
•2 min
Pharmaceutical Executive Daily: What It Takes to Move Machine Learning
•3 min
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
•4 min
Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs
•3 min
Rethinking Pharma's Go-to-Market Formula
•21 min
Pharmaceutical Executive Daily: FDA Approves Baxdrostat
•2 min
Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
•3 min
Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi
•4 min
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
•3 min
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
•3 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.